-- Arcadia and Roosevelt Resources terminate proposed business combination --
-- Exercise of preferred investment options yields $2.1 million gross proceeds --
DALLAS, March 26, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the fourth quarter and full year of 2025.
"At the end of 2025, we received a termination notice from Roosevelt Resources related to the Securities Exchange Agreement concerning a proposed business combination, signed in December 2024." said T.J. Schaefer, CEO of Arcadia.
Schaefer continued, "After receiving this news, we took steps to improve our balance sheet by entering into definitive agreements for the immediate exercise of certain outstanding preferred investment options, resulting in gross proceeds of approximately $2.1 million to Arcadia. We intend to use these proceeds, along with our other assets, to continue growing our Zola® coconut water brand while we evaluate strategic alternatives.
"In 2025, Zola sales growth continued to outpace the coconut water category. At the same time, we reduced our SG&A expenses by approximately 27%, and our net cash used in operating activities declined by 49% in 2025 compared to 2024," Schaefer added.
Arcadia Biosciences, Inc.
Financial Snapshot
(Unaudited)
($ in thousands)
Three months ended Dec 31
Twelve months ended Dec 31
2025
2024
Favorable/(Unfavorable)
2025
2024
Favorable/(Unfavorable)
$
%
$
%
Total Revenues
901
